. Overview At Erasca, our name is our mission: to eras e ca ncer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with cancer globally each year. Our compan...
Q2 FY2026 — expected 2026-08-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-12 | 2025-12-31 | 0001193125-26-104150 | EDGAR | 103K words |
| 2025-03-20 | 2024-12-31 | 0000950170-25-042682 | EDGAR | — |
| 2024-03-27 | 2023-12-31 | 0000950170-24-037193 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009496 | EDGAR | — |
| 2022-03-24 | 2021-12-31 | 0000950170-22-004557 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001193125-25-277625 | EDGAR | 27K words |
| 2025-08-12 | 2025-06-30 | 0001193125-25-178996 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070418 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125481 | EDGAR | — |
| 2024-08-12 | 2024-06-30 | 0000950170-24-095437 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055668 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062094 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041333 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-022282 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023926 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016907 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009720 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-12 | 0001193125-26-104105 | EDGAR | 3K words |
| 2026-01-29 | 0001193125-26-029467 | EDGAR | — |
| 2026-01-22 | 0001193125-26-019651 | EDGAR | — |
| 2026-01-20 | 0001193125-26-016556 | EDGAR | — |
| 2026-01-12 | 0001193125-26-009820 | EDGAR | — |
| 2025-11-12 | 0001193125-25-277571 | EDGAR | — |
| 2025-08-12 | 0001193125-25-178950 | EDGAR | — |
| 2025-06-26 | 0000950170-25-090493 | EDGAR | — |
| 2025-05-13 | 0000950170-25-070336 | EDGAR | — |
| 2025-03-20 | 0000950170-25-042659 | EDGAR | — |
81 total filings indexed. 54 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001761918 |
| Ticker | ERAS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.erasca.com |
| Listed | 2021-07-16 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report